Acceptance of Clinical Data for Scientific Publication - UnoMeter[TM] Safeti[TM] Max

26 May 2026 15:07 CEST

Oslo, 26 May 2026 - Observe Medical ASA (the "Company" or "Observe Medical") is
pleased to announce that an Abstract with in vitro clinical data related to the
Company's UnoMeter[TM] Safeti[TM] Max has been accepted for presentation and
publication by the International Continence Society.

The accepted Abstract presents findings from in vitro studies evaluating the
product's ability to protect patients from Catheter Associated Urinary Tract
infection (CAUTI), the most common hospital-acquired infection and a major
global healthcare burden, representing a multi-billion-dollar annual cost
through direct treatment expenses, prolonged hospitalization, and infection
-related complications.

The Company believes the acceptance represents an important scientific
validation of its technology and supports the continued commercial development
of the UnoMeter[TM] portfolio.

"We are very encouraged by the acceptance of these data for publication on a
respected scientific platform," said Jørgen Mann, CEO. "Peer-reviewed
publication is an important step in building scientific credibility and
increasing awareness of the value creation of our technology. We see that
UnoMeter[TM] Safeti[TM] Max has the potential of redefining protection against
catheter associated Urinary tract infection (CAUTI) and at the same time
offering healthcare providers with a health-economic contribution of managing
budget restraints and to support the sustainability agenda"

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available atwww.observemedical.com.

More information:
Access the news on Oslo Bors NewsWeb site

674484_Release.pdf